Published June 25, 2018 The collaborative Trajectory Analysis Program (cTAP), a multi-stakeholder, non-competitive global coalition in Duchenne muscular dystrophy today announced that Susan J. Ward, Ph.D., Executive Director of cTAP, will present at the 2018 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop Annual Conference in Washington DC on Thursday, September 13, 2018 at 1:15 p.m. EST. Debra Miller, CEO of CureDuchenne, a patient foundation in Duchenne that provided seed funding for cTAP and is a founding...

Summit Therapeutics Joins cTAP to Support the Development of Potential DMD Treatments Published September 29, 2017 The newly founded Collaborative Trajectory Analysis Project (cTAP) coalition of stakeholders has invited Summit Therapeutics, a company specialized in the discovery and development of drugs targeting Duchenne muscular dystrophy (DMD), to support the development of new therapeutic products aiming to treat DMD, such as utrophin modulators. cTAP was created to overcome the challenges of developing drugs for diseases characterized…

Published on PharmaVOICE Author: Denise Myshko The pressure on the pharmaceutical industry to bring innovative medications to the market — as well as address issues related to access, cost, and value — is requiring new ways of doing research and development. Couple this with how quickly science is advancing and the volume of data that is being created from many sources, it’s become clear to industry leaders R&D is not something that can be done…

Published on BioPharma Dive Author: Malorye A. Branca Creating a breakthrough drug is one of the highest risk ventures in healthcare: Success can mean billions of dollars in revenue for years to come, but failure can mean as much as a $1 billion wasted and a huge gap in a company’s product pipeline. “Clinical trials are very expensive, and the cost is only going up,” says Laurie Halloran, president of the Halloran Consulting Group. So shouldn’t…